Technical Blog | Battery Engineering & Compliance Series
Written by the TEFOO Medical Battery R&D Team · Last reviewed November 2026 · Next scheduled review May 2027
1. Introduction
If you design patient monitors, infusion pumps, portable ultrasound devices or hospital medical carts, you have probably seen the phrase “recycled content” appear in your suppliers’ ESG decks over the last twelve months. The driver is Regulation (EU) 2023/1542, the new EU Batteries Regulation that entered into force on 17 August 2023 and has been directly applicable across all Member States since 18 February 2024. As a battery engineer who has spent more than a decade qualifying Li-ion packs for Class II and Class III medical equipment under IEC 62133, IEC 60601 and ISO 13485, my honest assessment is this: the recycled-content quota in Article 8 of the Regulation does not directly hit the vast majority of portable medical battery packs before 2031, but the supply-chain, due-diligence and customer-pressure landscape behind it already is. Waiting for the legal deadline is the most expensive strategy.
This article walks through what 2023/1542 actually mandates on recycled cobalt, lithium, nickel and lead, which medical battery form-factors are and are not covered, the engineering reality of running regenerated active material through a medical-grade cell qualification, and how the supplier landscape is shaping up as of late 2026. A practical FAQ and a short buyer’s checklist close the piece.
2. The Recycled-Content Mandate Under EU 2023/1542
Article 8 of Regulation (EU) 2023/1542 establishes two distinct obligations. The first is a documentation duty: manufacturers of industrial batteries with a capacity greater than 2 kWh, EV batteries, LMT batteries and SLI batteries must declare, in the technical documentation, the percentage share of cobalt, lithium, nickel or lead contained in the active material that has been recovered either from battery manufacturing scrap (pre-consumer) or from end-of-life batteries (post-consumer). The second is a set of minimum thresholds that kick in on two fixed dates.
2.1 Minimum recycled-content thresholds in active materials
| Material | From 18 August 2031 | From 18 August 2036 |
| Cobalt (Co) | 16 % | 26 % |
| Lithium (Li) | 6 % | 12 % |
| Nickel (Ni) | 6 % | 15 % |
| Lead (Pb) | 85 % | 85 % |
| Applies to | Industrial batteries >2 kWh, EV, LMT, SLI | Same scope; 2029 review clause may tighten |
Table 1. Minimum recycled-content levels in active materials, Article 8(2)–(3), Regulation (EU) 2023/1542. Source: consolidated text 02023R1542 (EUR-Lex, updated 18 July 2024).
Two engineering points are easy to miss. First, the percentages are calculated on the metal mass present in the active material, not on the finished cell, the pack or the battery system. Second, the recovered metal must originate either from manufacturing waste scrap (a clean, traceable stream) or from post-consumer end-of-life batteries; off-spec mining tailings, primary metal production rejects and waste from non-battery industries do not count. The European Commission’s Joint Research Centre (JRC) published its technical study on the harmonised calculation and verification methodology in July 2026, and a Commission Delegated Regulation fixing the mass-balance chain-of-custody rules is now in the notification stage (draft reference EU1233). Until that delegated act enters into force, the exact accounting rule — especially whether recycled material can be allocated across production lines under a mass-balance approach — remains the single biggest commercial uncertainty in the whole Article 8 package.
2.2 Parallel targets: recovery efficiency, not just recycled input
The Regulation also sets end-of-life recovery targets in Annex XII. Cobalt, copper, lead and nickel recovery from waste batteries must reach 90 % by the end of 2027 and 95 % by the end of 2031; lithium recovery must reach 80 % by the end of 2031. A 2026 Commission report reviewed whether these targets needed to be revised and concluded that the balance between ambition and feasibility is broadly appropriate. For battery OEMs, this matters because the recycled-content supply that exists in 2031 will be physically constrained by how much recovered metal the European recycling ecosystem can actually output between now and then.
3. Does the Recycled-Content Quota Actually Apply to Medical Batteries?
This is the question every medical-device client asks us first, and the honest answer requires classifying the pack under the Regulation, not under MDR 2017/745. The 2023/1542 categories are portable, LMT, EV, industrial and SLI. A battery falls into a category by design, weight and intended use, not by the medical device it powers.
3.1 Portable medical battery packs — mostly outside the Article 8 quota
The majority of batteries used in patient monitors, infusion pumps, syringe pumps, portable ventilators, defibrillators, handheld diagnostic devices and surgical power tools weigh less than 5 kg and are not permanently connected to a fixed installation. Under Article 3 they are classified as portable batteries. The mandatory recycled-content thresholds in Article 8(2)–(3) do not apply to portable batteries. What does apply to them, however, is the full battery due-diligence regime (Articles 47–53) covering cobalt, lithium, nickel and natural graphite, the carbon-footprint declaration that is phased in for portable rechargeable cells, the collection-rate trajectory (a binding 63 % waste collection rate by the end of 2027), and the separate mercury/cadmium substance restrictions already in force since 18 February 2024.
3.2 Medical carts, large imaging systems and >2 kWh packs — inside the quota
Battery packs used in mobile workstations, hospital monitoring carts, large portable X-ray systems, UPS-type backup packs in imaging suites and off-grid diagnostic stations frequently exceed 2 kWh and are not portable by design. Those batteries are classified as industrial batteries and therefore fall directly under the Article 8 minimum recycled-content thresholds from 18 August 2031. If you ship a 48 V / 5 kWh LiFePO4 cart battery into the EU, the 2031 6 % lithium recycled minimum is a hard border, not a voluntary claim.
3.3 Implantable and subcutaneous-delivery devices — special treatment
Implantable active medical devices and certain in-vitro diagnostic devices are expressly recognised in the Regulation and in the July 2026 Commission Delegated Act on portable battery removability as relevant to the Article 11(3) derogation. On-body delivery systems specifically designed for subcutaneous administration of medicinal products are also on the derogation list. These devices are not expected to satisfy consumer-facing removability/replaceability requirements, because opening the battery compartment in the field would compromise sterility, seal integrity or patient safety. Note that this derogation covers removability, not recycled content — but because implantable packs are typically well below 2 kWh and are treated as specialised portable batteries, the Article 8 quota does not reach them either. They remain subject, however, to the Regulation’s marking, documentation and end-of-life obligations.
4. Technical Realities: Can Recycled Active Material Meet Medical-Grade Quality?
From an R&D bench perspective, the quality argument against recycled cathode material is weaker in 2026 than it was in 2020, but it has not disappeared. Three parameters dominate a medical-grade cell qualification and they are exactly the three that recycled streams struggle to control.
4.1 Magnetic impurity control
Ferromagnetic particles (Fe, Cr, Ni, Zn) above roughly 3 ppm in a cathode coating are the classic root cause of internal micro-shorts in Li-ion cells — and internal micro-shorts are precisely the failure mode a patient monitor cannot tolerate. Modern hydrometallurgical and direct-recycling lines report magnetic impurity levels below 3 ppm in regenerated LiFePO4 and NMC powders, which is at parity with virgin material. The practical implication is that recycled material is acceptable only when the recycler provides batch-level ICP and magnetic-separation certificates per lot, and the cell maker independently re-verifies incoming powder before coating. A certificate that says “meets industry average” is not sufficient for IEC 62133 Type Approval on a medical pack.
4.2 Crystal structure, cycle life and thermal stability
Spent cathodes degrade along three axes: transition-metal dissolution into the electrolyte, micro-cracking of secondary particles, and surface rock-salt phase reconstruction. Pyrometallurgical recycling melts these elements down and rebuilds the precursor from scratch — chemistry is clean, but the carbon and lithium are lost in the furnace. Hydrometallurgical leaching and co-precipitation rebuild NMC/NCA precursors with composition control comparable to virgin material; published 2025–2026 work on molten-salt upcycling of spent NMC532 into high-voltage NMC712 demonstrates regenerated single-crystal cathodes with thermal stability equal to or better than commercial NMC811 at matched capacity. Direct regeneration (relithiation + surface coating repair) is the most energy-efficient route and, for LiFePO4, already delivers rate capability and low-temperature performance close to virgin powder. For a medical pack that must hold 500 cycles at 80 % capacity retention over a 5–7 year service life, a blended supply — 30–50 % regenerated NMC/LFP in the cathode mix — is today’s engineering sweet spot; 100 % recycled cathodes are still a second-qualification project for most OEMs.
4.3 Traceability and chain of custody
Article 8 documentation is, at its core, a mass-balance provenance problem. A medical pack must be able to show, on demand from a Notified Body or a market-surveillance authority, which fraction of the cobalt, nickel or lithium in the active material is post-consumer recycled, and through which custody chain it arrived. This is why the JRC July 2026 methodology matters: until the delegated act is adopted, the defensible path is to specify recycled material as a separately sourced, batch-traced stream rather than to blend it invisibly into a generic commodity cathode. For ISO 13485 quality systems, this is a supplier-qualification project, not a purchase-order line change.
5. How Medical Battery Suppliers Compare on Recycled-Content Readiness
The supplier landscape falls into three camps. The table below summarises, as of late 2026, the typical position of each camp rather than a claim about any single company. We use it internally when scoping an OEM customer’s 2031 compliance roadmap.
| Supplier camp | Typical recycled-content position | Medical-grade qualification | Practical note for OEMs |
| Asian cell makers with captive recycling (CATL, EVE, LG ES, Samsung SDI) | Public sustainability roadmaps cite multi-percent recycled Co/Ni targets by the late 2020s; actual certified batch volumes still ramping | IEC 62133, UN 38.3, UL 1642 in place; medical pack integration typically via third-party BMS | Best cost/scale; ask for batch-level recycled-mass declaration and the specific public roadmap reference, not marketing claims |
| Western / Northvolt-linked cell makers | Strongest recycled-Li and closed-loop public commitments; smaller shipped volume in 2026 | IEC 62133, UN 38.3; limited medical-track record at pack level | Useful for EU-localisation and carbon-footprint story; watch production yield |
| Specialist medical pack integrators (TEFOO and comparable houses) | Blended cathode sourcing; targeting qualification of low-single-digit recycled-Co/Ni blended lots in customer pilot programmes by 2027, with documented chain of custody | ISO 13485, IEC 62133, IEC 60601-1, UN 38.3, smart BMS, SMBus / HDQ, custom form factors | Fastest route for medical OEMs: recycled content is engineered into the pack, not negotiated upstream |
| Pure recyclers selling cathode powder (Redwood, Accurec, Duesenfeld-type) | High-purity regenerated Co/Ni/Li salts and direct-recycled NMC/LFP powder; no finished cells | Material-level certs only; cell qualification is the buyer’s responsibility | Best for Tier-1 cell makers; most medical OEMs should buy finished cells, not powder |
| Lead-acid industrial backup (legacy UPS in imaging) | Already at 85 % recycled Pb, essentially compliant | IEC 61056, hospital-grade | Little change; watch lithium displacement trend |
Table 2. Recycled-content readiness across the medical battery supply chain, qualitative assessment Q4 2026. Company names are illustrative of each camp; percentages are public-roadmap targets, not certified performance.
The strategic takeaway for a medical-device OEM is not to wait for a “recycled medical cell” to appear on a distributor shelf. The near-term compliant path is to specify a pack integrator that (a) already runs ISO 13485 and IEC 62133, (b) can separate recycled-mass incoming material at the BOM level, and (c) builds a smart BMS that logs cycle, temperature and state-of-health data — because the same data chain that supports medical safety reporting will be the chain-of-custody evidence 2031 auditors ask for.
6. Frequently Asked Questions
Q1. Does Regulation (EU) 2023/1542 force me to use recycled materials in my patient monitor battery today?
No. The mandatory recycled-content minimums in Article 8 do not apply to portable batteries, and most patient-monitor packs are portable. The hard dates are 18 August 2031 and 2036, and they bite first on industrial batteries above 2 kWh, EV, LMT and SLI. What applies today is the due-diligence obligation for cobalt, lithium, nickel and natural graphite, plus mercury/cadmium substance limits and the evolving carbon-footprint declaration framework.
Q2. Our implantable pacemaker battery — are we covered by the removability derogation?
Implantable active medical devices and certain in-vitro diagnostic devices are recognised in Article 11(3) and in the July 2026 Delegated Act as entitled to derogation from portable-battery removability and replaceability requirements. On-body subcutaneous drug-delivery systems are also listed. This derogation is about user-replaceability, not about recycled content; it does not waive marking, end-of-life or due-diligence duties.
Q3. Is a battery made with recycled cathode material less safe than a virgin one?
Not in 2026, provided the material is supplied with batch-level magnetic-impurity, ICP-composition and crystal-structure certificates, and the cell maker re-qualifies the lot. Independent studies of direct-regenerated LFP and upcycled NMC cathodes show cycle life and thermal stability at parity with virgin material. The risk is not the chemistry; it is an under-controlled supply chain. For medical packs, require the same IEC 62133, UN 38.3 and (where applicable) IEC 60601-1 testing on recycled lots as on virgin lots.
Q4. How do we actually document “6 % recycled lithium” on a technical file?
The exact mass-balance accounting rule is still being fixed by a Commission Delegated Act (draft EU1233) following the JRC July 2026 methodology study. In practice, the defensible approach today is to source recovered Li/Co/Ni as a separately traced input, keep recycler certificates and cell-maker batch records, and report the percentage on the active-material mass, not on pack weight. Do not rely on a generic industry-average number.
Q5. We sell into the EU via a distributor. Who is the “manufacturer” responsible for Article 8?
Under the Regulation, the party that places the battery on the EU market — usually the OEM whose name appears on the label, or the importer if the OEM is outside the EU — is the economic operator responsible. Distributors have duty-of-care obligations but do not normally own the technical documentation. Confirm this in your EU distributor agreement; do not assume the importer will voluntarily carry your Article 8 file.
Q6. What should we ask our battery supplier for in our 2027 RFQ?
Four things: (1) a written recycled-content supply plan with target percentages per metal for 2028 and 2031; (2) ISO 13485 plus IEC 62133 and UN 38.3 certificates; (3) batch-level magnetic-impurity and ICP data on recycled cathode lots; and (4) a smart BMS with SMBus/HDQ communication and logged SOH data that can later serve as chain-of-custody evidence.
7. Conclusion
Regulation (EU) 2023/1542 is not, in 2026, a recycled-content emergency for portable medical battery packs. The Article 8 quotas — 16 % cobalt, 6 % lithium, 6 % nickel from August 2031, stepping up to 26 / 12 / 15 % in August 2036 — bite first on industrial packs above 2 kWh, EV and SLI batteries. But the direction of travel is unambiguous: the due-diligence regime, the carbon-footprint declarations, the 2027 waste-collection target and the 2027/2031 recovery-efficiency targets are already reshaping who can supply a qualifiable medical cell into the EU.
For medical-device OEMs, the engineering risk is not that recycled chemistry is unsafe — by 2026 the published data shows regenerated NMC and LFP powders can match virgin performance when impurity and crystal-structure controls are tight. The risk is being caught in 2030 with an un-qualified supply chain, an incomplete chain-of-custody file, and a Notified Body asking questions your quality system did not prepare for. Starting a recycled-content supplier qualification in 2027 — blended cathode streams, batch traceability, smart-BMS data logging — buys you three years of margin against a 2031 deadline that the Regulation’s 2029 review clause could tighten further.
At TEFOO, our medical-grade Li-ion packs already ship with ISO 13485, IEC 62133, IEC 60601-1, UN 38.3 and smart BMS platforms supporting SMBus and HDQ. We are currently qualifying blended recycled-cathode lots for customer programmes targeting EU 2031 compliance, with the batch-level documentation a Notified Body will expect. If you are scoping a next-generation patient monitor, infusion pump or mobile medical cart, the recycled-content conversation belongs in your BOM review, not in your 2030 fire drill.
Editorial & Conflict-of-Interest Disclosure
TEFOO is a manufacturer of medical and industrial Li-ion battery packs. This article is written for technical education and compliance planning purposes, reflects the author’s engineering judgement based on publicly available Regulation texts and peer-reviewed literature, and does not constitute legal, regulatory or medical-device-approval advice. Battery classification under Regulation (EU) 2023/1542 depends on intended use, weight and design; OEMs should confirm the classification of any specific pack with their Notified Body or a qualified EU regulatory counsel before placing it on the market. The supplier-camp table in Section 5 is a qualitative planning aid, not a certification; company names are illustrative and no percentage cited there should be read as a contractually committed figure.
References
– Regulation (EU) 2023/1542 of the European Parliament and of the Council of 12 July 2023 concerning batteries and waste batteries, consolidated text 18 July 2024, EUR-Lex CELEX:02023R1542. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02023R1542-20240718
– European Commission, “Sustainability rules for batteries and waste batteries,” EUR-Lex LEGISSUM:4704179, updated 2026. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISSUM:4704179
– European Commission Joint Research Centre, “Study on harmonised rules for the calculation and verification of recycled content in batteries,” JRC146717, July 2026. https://publications.jrc.ec.europa.eu/repository/handle/JRC146717
– Commission Delegated Regulation (EU) on derogations for the removability and replaceability of portable batteries, C(2026) 5031, 14 July 2026. https://environment.ec.europa.eu/
– European Commission, Report on the assessment of revising recycling efficiency and recovery targets in Annex XII to Regulation (EU) 2023/1542, ST 13060 2026 INIT, Council of the EU, 2026.
– Li, J. et al., “Molten-Salt-Mediated Upcycling of Spent LiNi0.5Co0.2Mn0.3O2 Cathodes into High-Voltage Stable LiNi0.7Co0.1Mn0.2O2,” Advanced Energy and Sustainability Research (2025). DOI: 10.1002/aesr.202500137.
– “Direct Repair of the Crystal Structure and Coating Surface of Spent LiFePO4 Materials Enables Superfast Li-Ion Migration,” Nature Communications / PMC12765765, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12765765/
